Non-invasive brain stimulation in neurology : Transcranial direct current stimulation to enhance cognitive functioning.

[Non-invasive brain stimulation in neurology : Transcranial direct current stimulation to enhance cognitive functioning]. Nervenarzt. 2016 May 11; Authors: Antonenko D, Flöel A Abstract Transcranial direct current stimulation (tDCS) has been successfully used in neuroscientific research to modulate cognitive functions. Recent studies suggested that improvement of behavioral performance is associated with tDCS-induced modulation of neuronal activity and connectivity. Thus, tDCS may also represent a promising tool for reconstitution of cognitive functions in the context of memory decline related to Alzheimer's disease or aphasia following stroke; however, evidence from randomized sham-controlled clinical trials is still scarce. Initial results of tDCS-induced behavioral improvement in patients with Alzheimer's dementia and its precursors indicated that an intense memory training combined with tDCS may be effective. Early interventions in the stage of mild cognitive impairment could be crucial but further evidence is needed to substantiate this. In patients with aphasia following stroke tDCS was applied to the left and right hemispheres, with varying results depending on the severity of the symptoms and polarity of the stimulation. Patients with mild aphasia can benefit from tDCS of the language dominant hemisphere while in patients with severe aphasia tDCS of right hemispheric homologous brain language areas may be particularly relevant. Moreover, rec...
Source: Der Nervenarzt - Category: Neurology Authors: Tags: Nervenarzt Source Type: research

Related Links:

ConclusionAccording to the results, whey supplementation significantly reduced the SBP, DBP, HDL, waist circumference, TG and FBS in intervention groups in comparing to control groups.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Interruption of oral anticoagulation, marijuana and stroke, ORBITA substudy, ISCHEMIA medical therapy targets, and more on AHA are the topics discussed by Dr. John Mandrola in this week ’ s on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news
Date: Tuesday, 12 03, 2019; Speaker: Leonardo Cohen, M.D. , Chief, Human Cortical Physiology and Neurorehabilitation Section, National Institute of Neurological Disorders and Stroke (NINDS) ; Building: Building 10 (Clinical Center); Lipsett Amphitheater
Source: NIH Calendar of Events - Category: American Health Source Type: events
Publication date: Available online 14 November 2019Source: NeuroImageAuthor(s): Maria Julieta Mateos, Alfonso Gastelum Strozzi, Fernando A. Barrios, Ernesto Bribiesca, Sarael Alcauter, Jorge Marquez FloresAbstractA voxel-based method for measuring sulcal width was developed, validated and applied to a database. This method (EDT-based LM) employs the 3D Euclidean Distance Transform (EDT) of the pial surface and a Local Maxima labeling algorithm. A computational phantom was designed to test method performance; results revealed the method's inaccuracy δ, to range between 0.1 and 0.5 voxels, for a width that varied betwe...
Source: NeuroImage - Category: Neuroscience Source Type: research
Conclusions. These results hold promise in improving the understanding of brain deterioration in stroke patients and the re-arrangement of brain networks. Furthermore, shows the use of functionality based brain modeling.
Source: Journal of Neuroscience Methods - Category: Neuroscience Source Type: research
Wei Li1†, Wei-Min Xiao1†, Yang-Kun Chen1*, Jian-Feng Qu1, Yong-Lin Liu1, Xue-Wen Fang2, Han-Yu Weng1 and Gen-Pei Luo11Department of Neurology, Dongguan People’s Hospital, Dongguan, China2Department of Radiology, Dongguan People’s Hospital, Dongguan, ChinaBackground: Anxiety is prevalent after a stroke. The pathophysiological mechanisms underlying the development of poststroke anxiety (PSA) remain unclear. The aim of this study was to investigate the clinical and neuroimaging risk factors for development of PSA and examine the effects of PSA on activities of daily living (ADL) and quality of life (...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
Vincenzo Tigano1, Giuseppe Lucio Cascini2, Cristina Sanchez-Castañeda3, Patrice Péran4 and Umberto Sabatini5* 1Department of Juridical, Historical, Economic and Social Sciences, University of Magna Graecia, Catanzaro, Italy 2Department of Experimental and Clinical Medicine, University of Magna Graecia, Catanzaro, Italy 3Department of Clinical Psychology and Psychobiology, University of Barcelona, Barcelona, Spain 4ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France 5Department of Medical and Surgical Sciences, University of Magna Graecia, Catanzaro, Ita...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Conclusions:Elevated CSF Tau levels in AD patients could be surrogate biomarker for AD subtypes with predominant early cortical symptoms and atrophy. There is a need for a systematic prospective unbiased follow-up to see if rapid clinical progression in AD is related to elevated T-Tau and distinct AD subtypes.Disclosure: Dr. Pillai has nothing to disclose. Dr. Khrestian has nothing to disclose. Dr. Bekris has nothing to disclose. Dr. Safar has nothing to disclose. Dr. Leverenz has received personal compensation for activities with Axovant, GE Healthcare and Navidea Biopharmaceuticals as a consultant.
Source: Neurology - Category: Neurology Authors: Tags: Aging and Dementia: Biomarkers Source Type: research
This article does not include any meta-analysis and aims simply at providing a comprehensive overview of the raw data reported in this field to date, as an aid to researchers.
Source: Neurophysiologie Clinique - Category: Neuroscience Source Type: research
Worldwide,  nearly44 million  people now have Alzheimer's disease (AD) or related dementia, making these conditions the  top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were hi...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
More News: Alzheimer's | Aphasia | Brain | Clinical Trials | Dementia | Neurology | Stroke | Study | Training | Universities & Medical Training